Drug intelligence / Profile preview

AB-2-81

Development stage: Preclinical
Lead developer: University of Central Florida
Modality: Small Molecules

Overview

AB-2-81 is a preclinical reserpine derivative developed by the University of Central Florida and the University of Florida. It was discovered using a "Complexity to Diversity" ring distortion approach on the indole alkaloid reserpine to generate novel antiplasmodial compounds. AB-2-81 exhibits potent antiplasmodial activity against *Plasmodium falciparum* (EC50 of 131 ± 21 nM) with high selectivity (selectivity index >191). It inhibits the early asexual blood stages (ring and trophozoite) of the parasite and shows promising liver-stage activity, making it a potential dual-stage antimalarial candidate.

Beyond the preview

Go deeper on AB-2-81.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-2-81.